Ranibizumab vs. pegaptanib: a cost-effectiveness study?
- PMID: 20424851
- DOI: 10.1007/s00417-010-1390-1
Ranibizumab vs. pegaptanib: a cost-effectiveness study?
Comment on
-
Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration.Graefes Arch Clin Exp Ophthalmol. 2010 Apr;248(4):467-76. doi: 10.1007/s00417-009-1156-9. Epub 2009 Aug 11. Graefes Arch Clin Exp Ophthalmol. 2010. PMID: 19669678
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
